Nature’s Answer Introduces Natural Mullein-X™ Cough^ Syrup to Support a Healthy Respiratory System*

Nature’s Answer Introduces Natural Mullein-X™ Cough^ Syrup to Support a Healthy Respiratory System*The Mullein-X™ Line Consists of Cough^ Syrup, Immune and Relax Cough^ Syrup, and an On-The-Go Throat Soothing Spray. All three formulas include a blend of true 1:1 concentrated herbal extracts formulated utilizing Bio-Chelation® Technology, exclusive to Nature’s Answer.

Nature’s Answer, the company that has been at the forefront of herbal extracts since 1972, has developed a new natural cough syrup, Mullein-X™ Cough Syrup. It’s their latest addition to a line of successful natural mullein-based products. 

Nature’s Answer Mullein-X™ Cough Syrup is a natural blend of key herbal ingredients that was developed utilizing modern and traditional herbology perfected by Nature’s Answer for over 50 years. Mullein-X™ Cough Syrup is formulated to help clear mucus, help soothe the throat and support immune and upper respiratory health.* The exclusive proprietary blend includes herbs such as Mullein, Nettles, Plantain, Elecampane, Horehound and Marshmallow. Many of these herbs are known as soothing demulcents which can support upper respiratory health.*

And it’s not just our new Mullein-X™ Cough Syrup that utilizes this unprecedented combination of ingredients,” says Christopher Martir, Manager of Commercial Development & Innovation at Nature’s Answer. “All three of our Mullein-X™ products are made from a 1:1 proprietary blend of native herbal extracts historically used as expectorants and demulcents to support immune and upper respiratory health. Achieving this 1:1 blend extraction is a difficult process that requires a unique method created by Nature’s Answer called Bio-Chelation®. This proprietary method uses cold extraction to help maintain the natural constituents of the herb, enabling the herb to remain Holistically Balanced™ and for the extract to remain alcohol-free.” 

Martir says, “We’re proud to say that the Nature’s Answer Mullein-X™ line is also the only line of multi-system support formulas that are non-drowsy, alcohol-free, gluten-free, drug-free, preservative-free and contain the exclusive blend of Quik-Sorb®, made from natural ingredients to help aid the body’s natural ability to absorb*.

When you look at the ingredients of Mullein-X™ Immune and Relax Support and Mullein-X™ Throat Spray On The Go and the new Mullein-X™Cough Syrup, it’s easy to see that they’re unlike any other products available today. 

Nature’s Answer Mullein-X™ Immune and Relax Support is a natural blend of key herbal ingredients inspired to help support upper respiratory health, immune health and relaxation day or night.* Formulated to help clear mucus with added immune support from Black Elderberry and Zinc.* Unlike typical PM formulas that are designed to put you to sleep, Mullein-X™ is the only multi-system support formula with relaxing herbs like Chamomile, Passion Flower, and the Ayurvedic adaptogen Holy Basil, that will help calm you while providing maximum immune and respiratory support.* 

Nature’s Answer Mullein-X™ Throat Spray On The Go is a natural herbal blend inspired and developed to help soothe the throat, clear mucus, and support upper respiratory health.* Unlike typical throat sprays designed to numb the throat, Mullein-X™ On The Go is a powerful throat-soothing blend of Grapefruit Seed Extract, Olive Leaf, Ginger Root, Licorice Root, Slippery Elm Bark, and English Ivy to help soothe irritated throats.* All you have to do is spray the back of your throat and enjoy the soothing power of nature.

Maintaining the efficacy of our unique formula is just as important as the ingredients that we use,” says Dean D’Amelio, “that’s why every product in the Mullein-X™ line comes in a glass bottle. Glass packaging is more sustainable and recyclable when compared to plastic packaging.”

Product integrity has always been important to Nature’s Answer. The company was founded in 1972 by Frank D’Amelio, Sr. and to this day, Nature’s Answer remains a family-owned-and-operated business with the highest standards for its natural products and liquid herbal extracts, with uncompromising manufacturing processes perfected over its 50-year history and upheld through three generations of the D’Amelio family still going strong today. This long-term stewardship and personal attention are exceedingly rare in today’s natural products marketplace.

As one of America’s largest and oldest manufacturers of nutritional supplements, Nature’s Answer is an FDA-registered, pharmaceutically licensed herbal manufacturing and quality control facility and has one of the most impressive herbariums in the U.S.

To view all the details of the Nature’s Answer Mullein-X™ product line, as well as any of their other natural high-quality products visit the Mullein-X landing page. 

^ For coughs associated with hoarseness, dry throat, and irritants
*This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information:

Kasra Hoshmand

Dir. Brand Marketing

[email protected]


Original Source:

Nature’s Answer Introduces Natural Mullein-X™ Cough^ Syrup to Support a Healthy Respiratory System*

Irish MedTech Company Medihive Receives €7 Million Investment

Irish MedTech Company Medihive Receives €7 Million InvestmentThe business is now valued at €62 million following the investment. Medihive includes Ireland’s largest online doctor service The investment will be used to fuel international growth, drive R&D innovation and accelerate healthcare software developments. Medihive will recruit up to 42 key hires across sales, engineering, doctors and marketing departments, adding to the 130 people already working with the company.

Medihive, Ireland’s award-winning health technology platform, which includes, has secured an investment from ResMed, an international leader in digital health and cloud-connected medical device innovation, as well as existing shareholders including VentureWave Capital. The investment now values the business at €62 million.

Medihive is a software company built to transform medical processes that don’t work so patients can benefit from healthcare that does work. The business provides sophisticated software and clinical solutions to the healthcare, pharmacy and insurance industries, as well as direct to consumers and corporates via The company combines digital and clinical know-how to bring clients and their end users high-quality virtual care on a global scale. 

The €7 million investment announced today will be used to further increase the international growth of the business, drive investment and innovation in R&D and accelerate healthcare software developments. The company currently employs 130 people and it is expected this number will now increase by a further 42 employees over the next two years.

ResMed, whose cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases, enabling people to live healthier lives, has been working with Medihive since 2019 and now joins as an investor. ResMed Germany led deal negotiations on behalf of the organisation. As a result of their investment, ResMed will now take a seat on the board to work with the team to accelerate the growth of the business. 

Meanwhile, existing shareholders in Medihive have invested additional capital into the business. This follows the €3 million investment in August 2021 by VentureWave Capital, the private equity firm that focuses on entrepreneurial companies that make a positive social impact, are in vital sectors and address UN Sustainable Development Goals. At the time of VentureWave Capital’s €3 million in August 2021, the business was valued at €48 million. Today’s investment now values the company at €62 million, a significant 29% increase.

Noel McSweeney, Chairman of Medihive, said: “The investment from ResMed alongside the increased support from current shareholders demonstrates our shared passion for medical technology advancement and will allow Medihive and to further expand and develop our services while continuing to provide transformative digital healthcare solutions.”

Katrin Pucknat, President of ResMed Germany, said: “At ResMed, our mission is to change 250 million lives in 2025 in out-of-hospital care settings, and today’s announcement fits perfectly with that goal. Our work to date with Medihive has transformed the lives of our patients by making their care pathway less disjointed and allowing them to get diagnosed for sleep apnea outside of a hospital setting. ResMed places significant importance on innovation and this investment will enable both organisations to continue to be at the forefront of developments in healthcare technology. We look forward to supporting the team at Medihive as part of their board and believe this relationship will create new opportunities for us both while continuing to transform the healthcare industry.”

David Crimmins, CEO of MediHive, said: “Medihive builds solutions to deliver positive patient outcomes by removing friction from their care journeys. This investment now comes at a pivotal moment for Medihive. Over the last two and a half years, demand for our services has surged as organisations realised they can achieve better patient outcomes by blending smart health technology with their traditional health infrastructures. This investment will enable us to continue meeting this demand while also allowing us to scale and expand our services in the continually evolving telehealth market both in Ireland and internationally. It’s an exciting time for Medihive, and we’re really looking forward to working with ResMed and our current shareholders to continue to make advances and improvements in digital healthcare for patients and professionals in the industry alike.”

Alan Foy, Chairman and Managing Partner VentureWave Capital, said: “We are delighted to once again invest in Medihive alongside ResMed, a key strategic investor. As a successful Irish health technology business that’s making an impact on delivering digital health and patient outcomes, this investment demonstrates our continued support and confidence in Medihive’s business goals, global impact and strategic ambitions.

                       Inspiring a world where instant, frictionless access to healthcare is the norm.

                                                             Medihive, Welcome Tomorrow.

For more information, visit

Contact Information:

Breda Brown

PR Director

[email protected]

087 2487120

Viv Murphy

PR Senior Account Manager

[email protected]


Related Files

Related Images

Original Source:

Irish MedTech Company Medihive Receives €7 Million Investment